Zydus Lifesciences532321Sustainability report
NSRAL assigns overall ESG rating of 71; company placed in 'leader' category for financial year 2026
Zydus Lifesciences has been assigned an overall ESG rating of 71 for financial year 2026 by NSRAL, a SEBI registered ESG rating provider.
By ScoutQuest · · 1 min read
- Overall ESG Rating
- 71
- Rating Category
- 'leader'
- Rating Period
- financial year 2026
What the update says
- NSE Sustainability Ratings and Analytics Limited (NSRAL), a subsidiary of NSE Indices Limited and a group company of National Stock Exchange of India Limited, and a SEBI registered ESG Rating Provider, has assigned an overall ESG rating of 71 to Zydus Lifesciences for financial year 2026.
- The rating is covered under the category of 'leader'.
- The company states the report was received by email on October 15, 2026, at 17.29 hours.
- The update also notes that this is an unsolicited rating, and that NSRAL independently prepared the report based on data pertaining to the company available in the public domain.
What an ESG rating is
- ESG stands for Environmental, Social and Governance.
- An ESG rating is a score given by a rating agency on how a company is seen to perform on these three areas.
- It is a third-party assessment and is separate from the company's financial statements such as revenue or profit.
- In this case, the score is 71 for financial year 2026, and the agency has placed it in its 'leader' category.
Points to keep in mind
- The update states the rating is unsolicited, meaning it was not commissioned by the company.
- The update states the report was prepared from publicly available data.
- The letter is signed by Dhaval N. Soni, Company Secretary and Compliance Officer.
What this tells an investor
- The announcement is an update about a third-party ESG assessment of the company, with a stated score of 71 and a 'leader' category label for financial year 2026.
- Such disclosures are a way for investors to track how rating agencies view the company's environmental, social and governance practices over time.
Also from Zydus Lifesciences
Zydus Lifesciences Q2 FY27 results on Nov 4, 2026; post-results earnings call same day at 3:30 p.m. IST
24 Oct 2026
Zylidac Bio and Prolific Machines partner to scale Prolific's light-controlled biologics platform to GMP production
21 Oct 2026
Zydus receives USFDA approval for Estradiol and Levonorgestrel Transdermal System, eligible for 180-day CGT exclusivity
21 Oct 2026
More numbers
- Overall ESG rating assigned by NSRAL for financial year 202671
Source: BSE · 16 Oct 2026
Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.